InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Drug overdose is the number one cause of accidental death in Connecticut, where someone is more likely to die from a drug ...

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg ...

The rate of AEs among pediatric patients with presumed TB disease was increased for those who received higher vs lower doses of WHO-recommended first-line treatment.

Awareness Month, which seeks to raise recognition and push for research of this rare genomic imprinting disorder. PWS is estimated to affect about one in 20 000 individuals1 yet, until now, people ...

The use of a clinical decision support system significantly improves adherence to safer prescribing practices for older ...

Emergency medications must be available in unit dose, age-specific, and ready-to-administer forms whenever possible. Emergency medications must be stored in sealed or locked containers in a locked ...

This needs to be addressed. The relatively high level of recreational drug use is not reflected in the number of positive tests. This suggests that many players who use recreational drugs avoid ...

The Africa Centers for Disease Control and Prevention (Africa CDC) declared a public health emergency earlier this ... remains the only recognised drug treatment for mpox – there are three ...

The regulator has set a timeframe of 12th August for its review of the new drug application (NDA) and – if approved – brensocatib could become a much-needed treatment option for hundreds of ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...